1
|
James WA, Rosenberg AL, Wu JJ, Hsu S, Armstrong A, Wallace EB, Lee LW, Merola J, Schwartzman S, Gladman D, Liu C, Koo J, Hawkes JE, Reddy S, Prussick R, Yamauchi P, Lewitt M, Soung J, Weinberg J, Lebwohl M, Glick B, Kircik L, Desai S, Feldman SR, Zaino ML. Executive Summary: From the Medical Board of the National Psoriasis Foundation: Perioperative management of immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol 2024:S0190-9622(24)00497-3. [PMID: 38499181 DOI: 10.1016/j.jaad.2024.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 02/06/2024] [Accepted: 03/05/2024] [Indexed: 03/20/2024]
Affiliation(s)
- Warren A James
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Angela L Rosenberg
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Jashin J Wu
- Department of Dermatology, University of Miami Miller School of Medicine
| | - Sylvia Hsu
- Temple University School of Medicine, Philadelphia, Pennsylvania
| | | | | | - Lara Wine Lee
- Medical University of South Carolina, Charleston, South Carolina
| | - Joseph Merola
- Brigham and Women's Hospital Harvard Medical School, Boston, Massachusetts
| | | | | | - Clive Liu
- Bellevue Dermatology, Bellevue, Washington
| | - John Koo
- University of California, San Francisco Medical Center, San Francisco, California
| | | | - Soumya Reddy
- NYU Grossman School of Medicine, New York, New York
| | - Ron Prussick
- Washington Dermatology Center, Frederick, Maryland
| | - Paul Yamauchi
- Dermatology Institute & Skin Care Center Santa Monica, California
| | | | | | | | - Mark Lebwohl
- Icahn School of Medicine at Mount Sinai, New York, New York
| | | | | | | | - Steven R Feldman
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina;; Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina;; Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina;; Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Mallory L Zaino
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina;.
| |
Collapse
|
2
|
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol 2024; 25:299-314. [PMID: 38263353 PMCID: PMC10867086 DOI: 10.1007/s40257-024-00846-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/16/2024] [Indexed: 01/25/2024]
Abstract
BACKGROUND The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12 years with alopecia areata (AA). OBJECTIVE The objective of this study was to evaluate the safety of ritlecitinib in an integrated analysis of four studies in AA. METHODS Two cohorts were analyzed: a placebo-controlled and an all-exposure cohort. Proportions and study size-adjusted incidence rates (IRs) of adverse events (AEs) of interest and laboratory abnormalities are reported. RESULTS In the placebo-controlled cohort (n = 881; median exposure: 169 days), the proportion of ritlecitinib-treated patients with AEs was 70.2-75.4% across doses versus 69.5% in the placebo group; serious AEs occurred in 0-3.2% versus 1.9% for the placebo. A total of 19 patients permanently discontinued due to AEs (5 while receiving the placebo). In the all-exposure cohort (n = 1294), median ritlecitinib exposure was 624 days [2091.7 total patient-years (PY)]. AEs were reported in 1094 patients (84.5%) and serious AEs in 57 (4.4%); 78 (6.0%) permanently discontinued due to AEs. The most common AEs were headache (17.7%; 11.9/100 PY), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test (15.5%; 9.8/100 PY), and nasopharyngitis (12.4%; 8.2/100 PY). There were two deaths (breast cancer and acute respiratory failure/cardiorespiratory arrest). Proportions (IRs) were < 0.1% (0.05/100 PY) for opportunistic infections, 1.5% (0.9/100 PY) for herpes zoster, 0.5% (0.3/100 PY) for malignancies (excluding nonmelanoma skin cancer), and 0.2% (0.1/100 PY) for major adverse cardiovascular events. CONCLUSIONS Ritlecitinib is well tolerated with an acceptable safety profile up to 24 months in patients aged ≥ 12 years with AA (video abstract and graphical plain language summary available). TRIAL REGISTRIES ClinicalTrials.gov: NCT02974868 (date of registration: 11/29/2016), NCT04517864 (08/18/2020), NCT03732807 (11/07/2018), and NCT04006457 (07/05/2019).
Collapse
Affiliation(s)
- Brett King
- Yale School of Medicine, New Haven, CT, USA
| | | | | | - Lidia Rudnicka
- Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
| | - Pascal Joly
- Rouen University Hospital, INSERM 1234, Normandie University, Rouen, France
| | - Melinda Gooderham
- Skin Centre for Dermatology, Canada Probity Medical Research, Waterloo, ON, Canada
| | | | - Natasha A Mesinkovska
- Department of Dermatology and Dermatopathology, School of Medicine, University of California, Irvine, CA, USA
| | - Carle Paul
- Department of Dermatology, Toulouse University and INSERM infinity U1291, Toulouse, France
| | | | | | | | | | | | | |
Collapse
|
3
|
Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, Pinto Correia A, Natalie CR, Rodriguez Capriles C, Pierce E, Reifeis S, Gontijo Lima R, Armengol Tubau C, Laquer V, Weidinger S. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study. Dermatol Ther (Heidelb) 2023:10.1007/s13555-023-00942-y. [PMID: 37318750 DOI: 10.1007/s13555-023-00942-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 05/17/2023] [Indexed: 06/16/2023] Open
Abstract
INTRODUCTION Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clinical benefit in previous Phase 3 trials: ADvocate1 (NCT04146363), ADvocate2 (NCT04178967), and ADhere (NCT04250337). We report 52-week safety and efficacy outcomes from ADore (NCT04250350), a Phase 3, open-label study of lebrikizumab in adolescent patients with moderate-to-severe AD. The primary endpoint was to describe the proportion of patients who discontinued from study treatment because of adverse events (AEs) through the last treatment visit. METHODS Adolescent patients (N = 206) (≥ 12 to < 18 years old, weighing ≥ 40 kg) with moderate-to-severe AD received subcutaneous lebrikizumab 500 mg loading doses at baseline and Week 2, followed by 250 mg every 2 weeks (Q2W) thereafter. Safety was monitored using reported AEs, AEs leading to treatment discontinuation, vital signs, growth assessments, and laboratory testing. Efficacy analyses included Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body Surface Area (BSA), (Children's) Dermatology Life Quality Index ((C)DLQI), and Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety, and PROMIS Depression. RESULTS 172 patients completed the treatment period. Low frequencies of SAEs (n = 5, 2.4%) and AEs leading to treatment discontinuation (n = 5, 2.4%) were reported. Overall, 134 patients (65%) reported at least one treatment-emergent AE (TEAE), most being mild or moderate in severity. In total, 62.6% achieved IGA (0,1) with ≥ 2-point improvement from baseline and 81.9% achieved EASI-75 by Week 52. The EASI mean percentage improvement from baseline to Week 52 was 86.0%. Mean BSA at baseline was 45.4%, decreasing to 8.4% by Week 52. Improvements in mean change from baseline (CFB) to Week 52 were observed in DLQI (baseline 12.3; CFB - 8.9), CDLQI (baseline 10.1; CFB - 6.5), PROMIS Anxiety (baseline 51.5; CFB - 6.3), and PROMIS Depression (baseline 49.3; CFB - 3.4) scores. CONCLUSIONS Lebrikizumab 250 mg Q2W had a safety profile consistent with previous trials and significantly improved AD symptoms and quality of life, with meaningful responses at Week 16 increasing by Week 52. TRIAL REGISTRATION ClinicalTrials.gov identifier, NCT04250350.
Collapse
Affiliation(s)
- Amy S Paller
- Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
| | - Carsten Flohr
- St John's Institute of Dermatology, King's College London, London, UK
| | | | - Alan D Irvine
- Clinical Medicine, Trinity College Dublin, Dublin, Ireland
| | | | - Jennifer Soung
- Southern California Dermatology, Inc., Santa Ana, CA, USA
| | | | | | | | | | | | | | | | | | - Stephan Weidinger
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany
| |
Collapse
|
4
|
Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, Blauvelt A. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol 2023; 159:182-191. [PMID: 36630140 PMCID: PMC9857439 DOI: 10.1001/jamadermatol.2022.5534] [Citation(s) in RCA: 25] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Importance Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials. Objective To evaluate efficacy and safety of LEB combined with low- to mid-potency topical corticosteroids (TCS) in patients with moderate-to-severe AD. Design, Setting, and Participants The ADhere trial was a 16-week randomized, double-blinded, placebo (PBO)-controlled, multicenter, phase 3 clinical trial conducted from February 3, 2020, to September 16, 2021. The study was conducted at 54 outpatient sites across Germany, Poland, Canada, and the US and included adolescent (aged ≥12 to <18 years weighing ≥40 kg) and adult patients with moderate-to-severe AD. The treatment allocation ratio was 2:1 (LEB:PBO). Interventions Overall, 211 patients were randomized to subcutaneous LEB (loading dose of 500 mg at baseline and week 2, followed by 250 mg every 2 weeks [Q2W] thereafter) or PBO Q2W in combination with TCS for 16 weeks. Main Outcomes and Measures Efficacy analyses at week 16 included proportions of patients achieving Investigator's Global Assessment score of 0 or 1 (IGA [0,1]) with 2 or more points improvement from baseline, and 75% improvement in the Eczema Area and Severity Index (EASI-75). Key secondary end points included evaluation of itch, itch interference on sleep, and quality of life. Safety assessments included monitoring adverse events (AEs). Results The mean (SD) age of patients was 37.2 (19.3) years, 103 (48.8%) patients were women, 31 (14.7%) patients were Asian, and 28 (13.3%) patients were Black/African American. At week 16, IGA (0,1) was achieved by 145 (41.2%) patients in the LEB+TCS group vs 66 (22.1%) receiving PBO+TCS (P = .01); corresponding proportions of patients achieving EASI-75 were 69.5% vs 42.2% (P < .001). The LEB+TCS group showed statistically significant improvements in all key secondary end points. Most treatment-emergent adverse events (TEAEs) were nonserious, mild or moderate in severity, and did not lead to study discontinuation. The TEAEs frequently reported in the LEB+TCS group included conjunctivitis (7 [4.8%]), headache (7 [4.8%]), hypertension (4 [2.8%]), injection site reactions (4 [2.8%]), and herpes infection (5 [3.4%]) vs 1.5% or less patient-reported frequencies in the PBO+TCS group. Similar frequencies of patient-reported serious AEs following LEB+TCS (n = 2, 1.4%) and PBO+TCS (n = 1, 1.5%). Conclusions and Relevance In this randomized phase 3 clinical trial, LEB+TCS was associated with improved outcomes in adolescents and adults with moderate-to-severe AD compared with TCS alone, and safety was consistent with previously reported AD trials. Trial Registration ClinicalTrials.gov Identifier: NCT04250337.
Collapse
Affiliation(s)
- Eric L Simpson
- Department of Dermatology, Oregon Health & Science University, Portland
| | | | - Andreas Wollenberg
- LMU - Department of Dermatology and Allergology, Munich, Germany.,Department of Dermatology, Free University Brussels, University Hospital Brussels, Brussels, Belgium
| | - Stephan Weidinger
- Department of Dermatology, Christian Albrechts University of Kiel, Kiel, Germany
| | | | | | - Silvia Ferrucci
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dermatology Unit, Milan, Italy
| | | | | | - Wen Xu
- Eli Lilly and Company, Indianapolis, Indiana
| | | | | | | | | | | |
Collapse
|
5
|
Feldman SR, Gottlieb AB, Soung J, Augustin M, Gisondi P, Peterson L, Vanvoorden V, Ciaravino V, Gomez NN, Warren RB. 34310 Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial. J Am Acad Dermatol 2022. [DOI: 10.1016/j.jaad.2022.06.612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Gottlieb AB, Soung J, Pinter A, Tsai TF, Carrascosa JM, Maul JT, Khattri S, Lopez Pinto JM, Merola JF. 33272 Fatigue in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from the CIMPACT phase 3 trial. J Am Acad Dermatol 2022. [DOI: 10.1016/j.jaad.2022.06.704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Soung J, Cather JC, Gooderham M. 33054 Improvement in touch avoidance in patients with genital psoriasis treated with ixekizumab: 52-week results of a phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q). J Am Acad Dermatol 2022. [DOI: 10.1016/j.jaad.2022.06.309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HCH, Soung J, Fromowitz J, Guenthner S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. N Engl J Med 2021; 385:2219-2229. [PMID: 34879448 DOI: 10.1056/nejmoa2103629] [Citation(s) in RCA: 60] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Tapinarof cream is a topical aryl hydrocarbon receptor-modulating agent under investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin-17 and the skin-barrier proteins filaggrin and loricrin. METHODS We conducted two identical phase 3 randomized trials of tapinarof in patients with mild-to-severe plaque psoriasis. Adults with a baseline Physician's Global Assessment (PGA) score of 2 (mild) to 4 (severe) (on a scale from 0 to 4, with higher scores indicating more severe psoriasis) and a percent of total body-surface area affected of 3 to 20% were randomly assigned in a 2:1 ratio to use tapinarof 1% cream or vehicle cream once daily for 12 weeks. The primary end point, PGA response, was a PGA score of 0 (clear) or 1 (almost clear) and a decrease from baseline of at least 2 points at week 12. Secondary efficacy end points at week 12 were a reduction of at least 75% in the Psoriasis Area and Severity Index (PASI) score, a PGA score of 0 or 1, the mean change from baseline in the percent of body-surface area affected, and a reduction of at least 90% in the PASI score. Patient-reported outcomes were the mean changes from baseline to week 12 in the proportion of patients who had a decrease of at least 4 points in the Peak Pruritus Numeric Rating Scale (PP-NRS) score (range, 0 [no itch] to 10 [worst imaginable itch]), the PP-NRS total score, the Dermatology Life Quality Index total score, and the Psoriasis Symptom Diary score. RESULTS In trials 1 and 2, a total of 692 and 674 patients, respectively, were screened, with 510 and 515 patients being enrolled. A PGA response occurred in 35.4% of the patients in the tapinarof group and in 6.0% of those in the vehicle group in trial 1 and in 40.2% and 6.3%, respectively, in trial 2 (P<0.001 for both comparisons). Results for secondary end points and patient-reported outcomes were generally in the same direction as those for the primary end point. Adverse events with tapinarof cream included folliculitis, nasopharyngitis, contact dermatitis, headache, upper respiratory tract infection, and pruritus. CONCLUSIONS Tapinarof 1% cream once daily was superior to vehicle control in reducing the severity of plaque psoriasis over a period of 12 weeks but was associated with local adverse events and headache. Larger and longer trials are needed to evaluate the efficacy and safety of tapinarof cream as compared with existing treatments for psoriasis. (Funded by Dermavant Sciences; PSOARING 1 and 2 ClinicalTrials.gov numbers, NCT03956355 and NCT03983980, respectively.).
Collapse
Affiliation(s)
- Mark G Lebwohl
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Linda Stein Gold
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Bruce Strober
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Kim A Papp
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - April W Armstrong
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Jerry Bagel
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Leon Kircik
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Benjamin Ehst
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - H Chih-Ho Hong
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Jennifer Soung
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Jeff Fromowitz
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Scott Guenthner
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Stephen C Piscitelli
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - David S Rubenstein
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Philip M Brown
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Anna M Tallman
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| | - Robert Bissonnette
- From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.K.); Henry Ford Health System, Detroit (L.S.G.); Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell - both in Connecticut (B.S.); Probity Medical Research, Waterloo, ON (K.A.P.), the University of British Columbia and Probity Medical Research, Surrey (H.C.H.), and Innovaderm Research, Montreal (R.B.) - all in Canada; Keck School of Medicine, University of Southern California, Los Angeles (A.W.A.), and Southern California Dermatology, Santa Ana (J.S.) - both in California; the Psoriasis Treatment Center of Central New Jersey, East Windsor (J.B.); Skin Sciences, Louisville, KY (L.K.); Oregon Medical Research Center, Portland (B.E.); Dermatology of Boca, Boca Raton, FL (J.F.); the Indiana Clinical Trials Center, Plainfield (S.G.); and Dermavant Sciences, Morrisville, NC (S.C.P., D.S.R., P.M.B., A.M.T.)
| |
Collapse
|
9
|
Lio P, Soung J, Cather J, Casillas M, Ding Y, De Lozier AM, Chen YF, Simpson E. 26691 Rapid and concurrent improvements in the signs and symptoms of atopic dermatitis with baricitinib in the phase 3 study, BREEZE-AD5. J Am Acad Dermatol 2021. [DOI: 10.1016/j.jaad.2021.06.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Lio PA, Simpson EL, Han G, Soung J, Ball S, Sun L, Casillas M, DeLozier AM, Ding Y, Eichenfield LF. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. J DERMATOL TREAT 2021; 33:2057-2062. [PMID: 34176407 DOI: 10.1080/09546634.2021.1914308] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND Baricitinib previously demonstrated improvements in itch and sleep disturbance versus placebo in adults with moderate-to-severe atopic dermatitis (AD). OBJECTIVES Examine if itch and sleep improvements are associated with better quality of life (QoL) and productivity in patients with AD. METHODS Data were drawn from BREEZE-AD5 (NCT03435081). Itch and sleep improvement at Week 16 were defined using ≥4-point improvements in the Itch Numeric Rating Scale and ≥1.5 decreases in the number of nighttime awakenings since baseline, respectively. Patients with and without improvements were compared on Dermatology Life Quality Index (DLQI) and Work Productivity and Activity Impairment-AD scores. Changes from baseline were analyzed using ANCOVA with last observation carried forward. Proportions were analyzed using logistic regression with non-responder imputation. RESULTS Greater proportions of patients with versus without itch improvement indicated no impact of AD on QoL (37.7 vs. 1.8%). Patients with itch improvement had greater decreases in work time impaired (-29.3 vs. -5.6%). More patients with versus without sleep improvement reported no effect of AD on QoL (25.5 vs. 1.1%); patients with better sleep experienced larger reductions in work time spent impaired (-33.3 vs. -6.1%). CONCLUSIONS Patients with AD who experienced itch and sleep improvement had significantly better QoL and productivity.
Collapse
Affiliation(s)
- Peter A Lio
- Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | | | - George Han
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jennifer Soung
- Southern California Dermatology, Inc, Santa Ana, CA, USA
| | - Susan Ball
- Eli Lilly and Company, Indianapolis, IN, USA
| | - Luna Sun
- Eli Lilly and Company, Indianapolis, IN, USA
| | | | | | - Yuxin Ding
- Eli Lilly and Company, Indianapolis, IN, USA
| | - Lawrence F Eichenfield
- University of California San Diego, San Diego, CA, USA.,Rady Children's Hospital, San Diego, CA, USA
| |
Collapse
|
11
|
Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, Soung J, Bao W, Keininger D, Marfo K, Patekar M, Sharma A, Shete A, Lebwohl MG. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. JAMA Dermatol 2021; 157:43-51. [PMID: 33001147 PMCID: PMC7527940 DOI: 10.1001/jamadermatol.2020.3257] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Question What is the association of secukinumab with active tuberculosis (TB) development, TB
reactivation, and latent tuberculosis infection (LTBI) activation? Findings In this pooled cohort study of 12 319 patients with psoriasis, psoriatic
arthritis, or ankylosing spondylitis, spontaneous reporting of new LTBI while undergoing
secukinumab treatment was rare. No active cases of TB or LTBI reactivation were
reported. Meaning The findings of this study provide a broader understanding of the safety of secukinumab
and appear to support its long-term use in chronic systemic inflammatory conditions. Importance Approximately one-quarter of the global population have latent tuberculosis infection
(LTBI), and tuberculosis (TB) is accountable for more than 1.5 million deaths annually.
Methotrexate, cyclosporine, and tumor necrosis factor inhibitors may be associated with
increased risk of TB and LTBI reactivation, although data are limited on the risks of TB
with use of newer biologics. Objective To assess the association of secukinumab with reporting of active TB development, TB
reactivation, and LTBI activation as an adverse event (AE) in patients with psoriasis,
psoriatic arthritis, or ankylosing spondylitis. Design, Setting, and Participants This pooled cohort study pooled data from 28 clinical trials of secukinumab used in
psoriasis (17 phase 3 or 3b and 2 phase 4 trials), psoriatic arthritis (5 phase 3
trials), and ankylosing spondylitis (4 phase 3 trials). A search of the Novartis
Secukinumab Compound Pool Database was conducted for the 28 trials. All trial
participants who had received at least 1 approved subcutaneous dose of secukinumab (150
mg or 300 mg) were included. Before randomization in these trials, patients underwent
screening for TB. Patients with active TB were excluded, and patients with LTBI were
treated according to local guidelines. Data were analyzed from the start of treatment in
the individual studies through December 25, 2018. Main Outcomes and Measures Reporting of active TB or LTBI as an AE over a 5-year period using exposure-adjusted
incidence rates (EAIR; incidence rates per 100 patient-years). Results A total of 12 319 patients were included, of whom 8819 patients had psoriasis
(71.6%; 5930 men [67.2%]; mean [SD] age, of 44.9 [13.5] years), 2523 had psoriatic
arthritis (20.5%; 1323 women [52.4%]; mean [SD] age, 48.8 [12.1] years), and 977 had
ankylosing spondylitis (7.3%; 658 men [67.3%]; mean [SD] age, 42.3 [11.9] years). In the
total population, 684 patients (5.6%) had tested positive for LTBI at screening. Over 5
years, LTBI as an AE during secukinumab treatment was reported in 13 patients (0.1% of
12 319). Of these 13 patients, 6 had a prior positive LTBI test result, and 7 were
newly diagnosed as having LTBI. Four of the 7 patients had psoriasis (EAIR, 0.03; 95%
CI, 0.01-0.07), 1 had psoriatic arthritis (EAIR, 0.02; 95% CI, 0.00-0.11), and 2 had
ankylosing spondylitis (EAIR, 0.08; 95% CI, 0.01-0.28). No cases of active TB were
reported. Conclusions and Relevance This study found that LTBI reported as an AE after secukinumab treatment was uncommon
and appeared to support the use of secukinumab in chronic systemic inflammatory
conditions.
Collapse
Affiliation(s)
- Boni E Elewski
- University of Alabama at Birmingham, Department of Dermatology, Eye Foundation Hospital, Birmingham
| | - John W Baddley
- Department of Medicine and Infectious Diseases, University of Alabama at Birmingham, Birmingham
| | - Atul A Deodhar
- Department of Rheumatology, Oregon Health & Science University, Portland
| | - Marina Magrey
- Department of Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, Ohio
| | - Phoebe A Rich
- Department of Dermatology, Oregon Health & Science Center, Portland
| | - Enrique R Soriano
- Sección Reumatología, Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Jennifer Soung
- Department of Dermatology, Southern California Dermatology and Harbor UCLA (University of California, Los Angeles), Santa Ana
| | - Weibin Bao
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
| | | | | | | | | | | | - Mark Gabriel Lebwohl
- Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York
| |
Collapse
|
12
|
Menter A, Arenberger P, Balser S, Beissert S, Cauthen A, Czeloth N, Soung J, Jazayeri S, Weisenseel P, Jayadeva G. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. Expert Opin Biol Ther 2020; 21:87-96. [PMID: 33317345 DOI: 10.1080/14712598.2021.1851362] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Background: BI 695501 is an approved biosimilar to Humira® reference product (RP). Research design and methods: In this randomized Phase III trial (VOLTAIRE-PSO), patients with moderate-to-severe chronic plaque psoriasis received BI 695501 or adalimumab RP (24-week treatment). Primary efficacy endpoint: the proportion of patients with ≥75% reduction in Psoriasis Area and Severity Index (PASI 75) response at week 16 (±18% equivalence limits for two-sided 95% confidence interval between treatment groups). Safety, pharmacokinetics, and immunogenicity were also assessed. Results: Baseline characteristics were balanced between treated groups (BI 695501, n = 159; adalimumab RP, n = 158). PASI 75 response rates (full analysis set, n = 158; n = 157) were 68.2% (BI 695501) and 70.4% (adalimumab RP) at week 16 (95% CI: -14.4%, 8.7%), and 75.3% and 72.4%, at week 24, respectively. At week 24, 41.5% (BI 695501) and 44.9% (adalimumab RP) of treated patients had treatment-emergent adverse events (AEs), 3.1% and 4.4% had serious AEs, and 0.0% and 1.9% had AEs of special interest. Of treated patients, 75.3% (BI 695501) and 77.9% (adalimumab RP) were anti-drug antibody-positive. Conclusion: These data demonstrate equivalent efficacy and highly similar safety and immunogenicity between BI 695501 and adalimumab RP in patients with chronic plaque psoriasis. Study identifier: NCT02850965.
Collapse
Affiliation(s)
- Alan Menter
- Institute for Rehabilitation, Baylor Scott & White , Dallas, TX, USA
| | - Petr Arenberger
- Department of Dermatology and Venereology, University Hospital Kralovske Vinohrady , Prague, Czech Republic
| | - Sigrid Balser
- Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach an der Riss, Germany
| | - Stefan Beissert
- Department of Dermatology, Universitätsklinikum Carl Gustav Carus, TU Dresden , Dresden, Germany
| | | | - Niklas Czeloth
- Boehringer Ingelheim International GmbH , Ingelheim am Rhein, Germany
| | - Jennifer Soung
- Southern California Dermatology Inc ., Santa Ana, CA, USA
| | - Sasha Jazayeri
- Alliance Dermatology and Mohs Center PC , Phoenix, AZ, USA
| | | | - Girish Jayadeva
- Boehringer Ingelheim International GmbH , Ingelheim am Rhein, Germany
| |
Collapse
|
13
|
Krueger JG, Pariser D, Tyring SK, Bagel J, Alexis AF, Soung J, Armstrong AW, Muscianisi E, Kianifard F, Prasad Sarkar MR, Blauvelt A. 15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis. J Am Acad Dermatol 2020. [DOI: 10.1016/j.jaad.2020.06.234] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Elewski B, Baddley JW, Deodhar A, Magrey M, Rich P, Soriano E, Soung J, Bao W, Patekar M, Lebwohl M, Sharma A. 15261 Lack of tuberculosis reactivation in 12,319 patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab: An ad hoc analysis of pooled safety data from 28 clinical trials. J Am Acad Dermatol 2020. [DOI: 10.1016/j.jaad.2020.06.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Lebwohl M, Stein Gold L, Strober B, Armstrong A, Hong HCH, Kircik L, Soung J, Fromowitz J, Guenthner S, Piscitelli S, Rubenstein D, Brown P, Tallman A, Bissonnette R. Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials. ACTA ACUST UNITED AC 2020. [DOI: 10.25251/skin.4.supp.75] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Abstract not available.
Collapse
|
16
|
Papp K, Menter A, Leonardi C, Soung J, Weiss S, Pillai R, Jacobson A. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol 2020; 183:1037-1048. [PMID: 32286683 PMCID: PMC7754427 DOI: 10.1111/bjd.19132] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/07/2020] [Indexed: 12/30/2022]
Abstract
BACKGROUND Brodalumab is efficacious for the treatment of moderate-to-severe plaque psoriasis through 52 weeks. OBJECTIVES To evaluate the efficacy and safety of brodalumab through 120 weeks, including following withdrawal and retreatment. METHODS At baseline, patients were randomized to brodalumab (n = 222) or placebo (n = 220). At week 12, patients achieving a static Physician's Global Assessment (sPGA) score of 0 or 1 (sPGA 0/1) with brodalumab were rerandomized to brodalumab (n = 83) or placebo (n = 84; later re-treated with brodalumab if sPGA ≥ 3 occurred), and patients receiving placebo switched to brodalumab (n = 208). Safety was assessed by exposure-adjusted rates of treatment-emergent adverse events. RESULTS Among those who achieved sPGA 0/1 at week 12 and were rerandomized to brodalumab, 96% and 80% using observed data, respectively, and 74% and 61% using nonresponder imputation, respectively, achieved 75% improvement in Psoriasis Area and Severity Index (PASI 75) and PASI 100 at week 120. Following withdrawal from brodalumab, return of disease occurred after a mean ± SD duration of 74·7 ± 50·5 days. Among those who switched from brodalumab to placebo at week 12, PASI 75 rates using observed data and nonresponder imputation were 55% and 51% at week 20, respectively and 94% and 75% at week 120, respectively; PASI 100 rates at week 120 were 75% and 60%, respectively. Efficacy was maintained through week 120 in those receiving brodalumab after placebo. No new safety signals were observed. CONCLUSIONS These findings indicate that brodalumab is efficacious and safe for continuous long-term treatment of psoriasis, and support the potential for response after discontinuation and retreatment.
Collapse
Affiliation(s)
- K Papp
- Probity Medical Research and K Papp Clinical Research, Waterloo, ON, Canada
| | - A Menter
- Baylor Scott & White, Dallas, TX, USA
| | | | - J Soung
- Southern California Dermatology, Santa Ana, CA, USA
| | - S Weiss
- Direct Dermatology, Palo Alto, CA, USA
| | - R Pillai
- Bausch Health US, LLC, Petaluma, CA, USA
| | - A Jacobson
- Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ, USA
| |
Collapse
|
17
|
Green L, Weinberg J, Menter A, Soung J, Lain E, Jacobson A. Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis. J Drugs Dermatol 2020; 19:138-143. [DOI: 10.36849/jdd.2020.4645] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
18
|
Konstantinou M, Reich K, Soung J, Maari C, Gebauer K, Thaci D, Flavin S, Hsu M, Randazzo B, Blauvelt A. Amélioration du score PASI absolu chez des patients atteints de psoriasis traités par le guselkumab ou le sécukinumab: résultats de l’étude ECLIPSE. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Yosipovitch G, Soung J, Weiss J, Muscianisi E, Meng X, Gilloteau I, Elewski BE. Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials. Acta Derm Venereol 2019; 99:820-821. [PMID: 31017248 DOI: 10.2340/00015555-3195] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Gil Yosipovitch
- Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, 33136 Miami, USA.
| | | | | | | | | | | | | |
Collapse
|
20
|
Sugarman JL, Weiss JS, Tanghetti EA, Soung J, Yamauchi PS, Lin T, Harris S, Martin G, Pillai R. Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies. Cutis 2019; 103:111-116. [PMID: 30893392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Potent topical corticosteroids (TCSs) are the mainstay of psoriasis treatment. Safety concerns have limited use to 2 to 4 weeks. The objective of our study was to investigate the safety and efficacy of once-daily halobetasol propionate (HP) lotion 0.01% in moderate to severe plaque psoriasis through 2 multicenter, randomized, double-blind, vehicle-controlled phase 3 studies (N=430). Participants were randomized (2:1) to HP lotion 0.01% or vehicle once daily for 8 weeks, followed by 4 weeks of follow-up. The primary efficacy assessment was treatment success (at least a 2-grade improvement in baseline investigator global assessment [IGA] score and a score of 0 [clear] or 1 [almost clear]). Additional assessments included improvement in psoriasis signs and symptoms, body surface area (BSA), and a composite score of IGA×BSA. Safety and treatment-emergent adverse events (AEs) were evaluated throughout. We found that HP lotion 0.01% demonstrated statistically significant superiority over vehicle as early as week 2 and also was superior in reducing psoriasis signs and symptoms and BSA involvement.
Collapse
Affiliation(s)
| | - Jonathan S Weiss
- Gwinnett Dermatology, PC, and Gwinnett Clinical Research Center, Inc, Snellville, Georgia, USA
| | - Emil A Tanghetti
- Center for Dermatology and Laser Surgery, Sacramento, California, USA
| | | | - Paul S Yamauchi
- David Geffen School of Medicine at UCLA, Los Angeles, California, USA
| | - Tina Lin
- Ortho Dermatologics, Bridgewater, New Jersey, USA
| | | | | | | |
Collapse
|
21
|
Knuckles MLF, Levi E, Soung J. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast. J DERMATOL TREAT 2018; 30:430-434. [DOI: 10.1080/09546634.2018.1528326] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
|
23
|
Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol 2018; 32:397-402. [PMID: 29220542 PMCID: PMC5873268 DOI: 10.1111/jdv.14738] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Accepted: 11/22/2017] [Indexed: 01/20/2023]
Abstract
Background Apremilast, an oral phosphodiesterase‐4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. Objective To evaluate long‐term efficacy and safety of apremilast in biologic‐naive patients with moderate to severe plaque psoriasis and safety of switching from etanercept to apremilast in the phase 3b LIBERATE trial. Methods Two hundred fifty patients were randomized to placebo, apremilast 30 mg BID or etanercept 50 mg QW through Week 16; thereafter, all patients continued or switched to apremilast through Week 104 (extension phase). Skin, scalp and nail involvement at Weeks 16, 52 and 104 were assessed using the Psoriasis Area and Severity Index (PASI; 0–72), Scalp Physician Global Assessment (ScPGA; 0–5) and Nail Psoriasis Severity Index (NAPSI; 0–8); patient‐reported outcomes (PROs) were assessed using the Dermatology Life Quality Index (DLQI; 0–32) and pruritus visual analog scale (VAS; 0–100 mm). Results The apremilast‐extension phase (Weeks 16–104) included 226 patients in the placebo/apremilast (n = 73), apremilast/apremilast (n = 74) and etanercept/apremilast (n = 79) groups, and at Week 104, 50.7%, 45.9% and 51.9% of these patients, respectively, maintained ≥75% reduction from baseline in PASI score (based on last‐observation‐carried‐forward analysis). Across treatment groups, ScPGA 0 (clear) or 1 (minimal) was achieved by 50.0%–59.2% of patients; NAPSI mean change from baseline was −48.1% to −51.1%; DLQI score ≤5 was achieved by 66.0%–72.5% of patients; and pruritus VAS mean change from baseline was −24.4 to −32.3. AEs in ≥5% of patients (diarrhoea, nausea, nasopharyngitis, upper respiratory tract infection and headache) did not increase with prolonged apremilast exposure. Conclusions Apremilast demonstrated significant and sustained improvements in skin, scalp, nails and PROs (pruritus and quality of life) over 104 weeks in patients with moderate to severe plaque psoriasis. Safety was consistent with the known safety profile of apremilast.
Collapse
Affiliation(s)
- K Reich
- Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany
| | - M Gooderham
- SKiN Centre for Dermatology, Queen's University and Probity Medical Research, Peterborough, Ontario, Canada
| | - A Bewley
- Whipps Cross University Hospital, London, UK.,The Royal London Hospital, London, UK
| | - L Green
- George Washington University, School of Medicine, Washington, DC, USA
| | - J Soung
- Southern California Dermatology, Santa Ana, CA, USA
| | - R Petric
- Celgene Corporation, Summit, NJ, USA
| | | | - J Cirulli
- Celgene Corporation, Summit, NJ, USA
| | - R Chen
- Celgene Corporation, Summit, NJ, USA
| | - V Piguet
- Cardiff University and University Hospital of Wales, Wales, UK.,Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.,Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
24
|
Zanin-Zhorov A, Weiss JM, Trzeciak A, Chen W, Zhang J, Nyuydzefe MS, Arencibia C, Polimera S, Schueller O, Fuentes-Duculan J, Bonifacio KM, Kunjravia N, Cueto I, Soung J, Fleischmann RM, Kivitz A, Lebwohl M, Nunez M, Woodson J, Smith SL, West RF, Berger M, Krueger JG, Ryan JL, Waksal SD. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. J Immunol 2017; 198:3809-3814. [PMID: 28389592 DOI: 10.4049/jimmunol.1602142] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 03/21/2017] [Indexed: 11/19/2022]
Abstract
Targeted inhibition of Rho-associated kinase (ROCK)2 downregulates the proinflammatory T cell response while increasing the regulatory arm of the immune response in animals models of autoimmunity and Th17-skewing human cell culture in vitro. In this study, we report that oral administration of a selective ROCK2 inhibitor, KD025, reduces psoriasis area and severity index scores by 50% from baseline in 46% of patients with psoriasis vulgaris, and it decreases epidermal thickness as well as T cell infiltration in the skin. We observed significant reductions of IL-17 and IL-23, but not IL-6 and TNF-α, whereas IL-10 levels were increased in peripheral blood of clinical responders after 12 wk of treatment with KD025. Collectively, these data demonstrate that an orally available selective ROCK2 inhibitor downregulates the Th17-driven autoimmune response and improved clinical symptoms in psoriatic patients via a defined molecular mechanism that involves concurrent modulation of cytokines without deleterious impact on the rest of the immune system.
Collapse
Affiliation(s)
| | | | | | - Wei Chen
- Kadmon Corporation, LLC, New York, NY 10016
| | | | | | | | | | | | | | - Kathleen M Bonifacio
- Laboratory for Investigative Dermatology, Rockefeller University, New York, NY 10065
| | - Norma Kunjravia
- Laboratory for Investigative Dermatology, Rockefeller University, New York, NY 10065
| | - Inna Cueto
- Laboratory for Investigative Dermatology, Rockefeller University, New York, NY 10065
| | - Jennifer Soung
- Southern California Dermatology, Inc., Santa Ana, CA 92701
| | | | - Alan Kivitz
- Altoona Center for Clinical Research, Duncanville, PA 16635
| | - Mark Lebwohl
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029
| | | | | | - Shondra L Smith
- Dermatology & Advanced Aesthetics, Lake Charles, LA 70605; and
| | | | | | - James G Krueger
- Laboratory for Investigative Dermatology, Rockefeller University, New York, NY 10065
| | | | | |
Collapse
|
25
|
Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol 2016; 31:507-517. [PMID: 27768242 PMCID: PMC5363370 DOI: 10.1111/jdv.14015] [Citation(s) in RCA: 127] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 10/03/2016] [Indexed: 01/11/2023]
Abstract
Background Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate‐to‐severe psoriasis. Objective Evaluate efficacy and safety of apremilast vs. placebo in biologic‐naive patients with moderate‐to‐severe plaque psoriasis and safety of switching from etanercept to apremilast in a phase IIIb, randomized, double‐blind, placebo‐controlled study (NCT01690299). Methods Two hundred and fifty patients were randomized to placebo (n = 84), apremilast 30 mg BID (n = 83) or etanercept 50 mg QW (n = 83) through Week 16; thereafter, all patients continued or switched to apremilast through Week 104. The primary efficacy endpoint was achievement of PASI‐75 at Week 16 with apremilast vs. placebo. Secondary endpoints included achievement of PASI‐75 at Week 16 with etanercept vs. placebo and improvements in other clinical endpoints vs. placebo at Week 16. Outcomes were assessed through Week 52. This study was not designed for apremilast vs. etanercept comparisons. Results At Week 16, PASI‐75 achievement was greater with apremilast (39.8%) vs. placebo (11.9%; P < 0.0001); 48.2% of patients achieved PASI‐75 with etanercept (P < 0.0001 vs. placebo). PASI‐75 response was maintained in 47.3% (apremilast/apremilast), 49.4% (etanercept/apremilast) and 47.9% (placebo/apremilast) of patients at Week 52. Most common adverse events (≥5%) with apremilast, including nausea, diarrhoea, upper respiratory tract infection, nasopharyngitis, tension headache and headache, were mild or moderate in severity; diarrhoea and nausea generally resolved in the first month. No new safety or tolerability issues were observed through Week 52 with apremilast. Conclusion Apremilast demonstrated significant efficacy vs. placebo at Week 16 in biologic‐naive patients with psoriasis, which was sustained over 52 weeks, and demonstrated safety consistent with the known safety profile of apremilast. Switching from etanercept to apremilast did not result in any new or clinically significant safety findings, and efficacy was maintained with apremilast through Week 52.
Collapse
Affiliation(s)
- K Reich
- SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany
| | - M Gooderham
- SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada
| | - L Green
- George Washington University School of Medicine, Washington, DC, USA
| | - A Bewley
- Whipps Cross University Hospital & the Royal London Hospital, London, UK
| | - Z Zhang
- Celgene Corporation, Summit, NJ, USA
| | | | - R M Day
- Celgene Corporation, Summit, NJ, USA
| | | | - K Shah
- Celgene Corporation, Summit, NJ, USA
| | - V Piguet
- Cardiff University and University Hospital of Wales, Wales, UK
| | - J Soung
- Southern California Dermatology, Santa Ana, CA, USA
| |
Collapse
|
26
|
Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, Draelos Z, Mamolo C, Purohit V, Wang C, Ports WC. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol 2016; 16:15. [PMID: 27716172 PMCID: PMC5048458 DOI: 10.1186/s12895-016-0051-4] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/03/2016] [Accepted: 09/09/2016] [Indexed: 12/30/2022]
Abstract
Background Most psoriasis patients have mild to moderate disease, commonly treated topically. Current topical agents have limited efficacy and undesirable side effects associated with long-term use. Tofacitinib is a small molecule Janus kinase inhibitor investigated for the topical treatment of psoriasis. Methods This was a 12-week, randomized, double-blind, parallel-group, vehicle-controlled Phase 2b study of tofacitinib ointment (2 % and 1 %) applied once (QD) or twice (BID) daily in adults with mild to moderate plaque psoriasis. Primary endpoint: proportion of patients with Calculated Physician’s Global Assessment (PGA-C) clear or almost clear and ≥2 grade improvement from baseline at Weeks 8 and 12. Secondary endpoints: proportion of patients with PGA-C clear or almost clear; proportion achieving Psoriasis Area and Severity Index 75 (PASI75) response; percent change from baseline in PASI and body surface area; change from baseline in Itch Severity Item (ISI). Adverse events (AEs) were monitored and clinical laboratory parameters measured. Results Overall, 435 patients were randomized and 430 patients received treatment. The proportion of patients with PGA-C clear or almost clear and ≥2 grade improvement from baseline at Week 8 was 18.6 % for 2 % tofacitinib QD (80 % confidence interval [CI] for difference from vehicle: 3.8, 18.2 %) and 22.5 % for 2 % tofacitinib BID (80 % CI: 3.1, 18.5 %); this was significantly higher vs vehicle for both dosage regimens. No significant difference vs vehicle was seen at Week 12. Significantly more patients achieved PGA-C clear or almost clear with 2 % tofacitinib QD and BID and 1 % tofacitinib QD (not BID) at Week 8, and with 2 % tofacitinib BID at Week 12. Pruritus was significantly reduced vs vehicle with 2 % and 1 % tofacitinib BID (starting Day 2), and 2 % tofacitinib QD (starting Day 3). Overall, 44.2 % of patients experienced AEs, 8.1 % experienced application site AEs, and 2.3 % experienced serious AEs. The highest incidence of AEs (including application site AEs) was in the vehicle QD group. Conclusions In adults with mild to moderate plaque psoriasis, 2 % tofacitinib ointment QD and BID showed greater efficacy than vehicle at Week 8, but not Week 12, with an acceptable safety and local tolerability profile. Trial registration NCT01831466 registered March 28, 2013. Electronic supplementary material The online version of this article (doi:10.1186/s12895-016-0051-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Kim A Papp
- K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada
| | | | - Melinda Gooderham
- SKiN Centre for Dermatology and Probity Medical Research Inc, Peterborough, and Queens University, Kingston, ON, Canada
| | | | | | | | - Zoe Draelos
- Dermatology Consulting Services, High Point, NC, USA
| | - Carla Mamolo
- Pfizer Worldwide Biopharmaceuticals, Global Innovative Pharma Business, Groton, CT, USA
| | - Vivek Purohit
- Pfizer Worldwide Biopharmaceuticals, Global Innovative Pharma Business, Groton, CT, USA
| | - Cunshan Wang
- Pfizer Worldwide Biopharmaceuticals, Global Innovative Pharma Business, Groton, CT, USA
| | - William C Ports
- Pfizer Worldwide Biopharmaceuticals, Global Innovative Pharma Business, Groton, CT, USA.
| |
Collapse
|
27
|
Reich K, Soung J, Gooderham M, Zhang Z, Nograles K, Day R, Ferris L, Goodfield M. THU0439 52-Week Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate To Severe Psoriasis: Results from The Liberate Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1732] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Abstract
BACKGROUND AND OBJECTIVE Psoriasis is a common, chronic autoimmune inflammatory skin disorder, which has potential systemic complications and is clinically defined by sharply demarcated, erythematous patches and plaques covered by a characteristic silvery white scale. Topical corticosteroids have widely been regarded as the mainstay first line of treatment. Recently, topical vitamin D analogs have been added to the first-line treatment repertoire as well, either as monotherapy or in combination with topical steroids due to synergistic, complementary effectiveness. In this paper, we review the role of vitamin D in the pathophysiology and treatment of psoriasis. METHODS A comprehensive search of the Cochrane Library, MEDLINE, and PUBMED databases were performed to identify relevant basic science and clinical trial literature investigating the role of vitamin D in psoriasis. Primary endpoints in clinical trials were largely based on clinical improvement as assessed by the psoriasis area severity index score or physician's global assessment. RESULTS AND CONCLUSION The role of vitamin D in psoriasis is complex and extensive. Oral and topical vitamin D therapies provide comparable efficacies to corticosteroids when used as monotherapy and may be superior when used in combination with a potent topical steroid. Additionally topical vitamin D analogs demonstrate a favorable safety profile with "steroid-sparing" effects. Thus, topical vitamin D derivatives should be considered an indispensable component of the current physician's arsenal in the treatment of psoriasis.
Collapse
Affiliation(s)
- Teo Soleymani
- Department of Dermatology, University of California, Irvine School of Medicine, Irvine, CA, USA
| | | | | |
Collapse
|
29
|
Uliasz A, Zeichner J, Soung J, Wong V, Lebwohl M. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses. Cutis 2008; 81:517-519. [PMID: 18666395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
To compare the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05%, 20 participants with corticosteroid-responsive dermatoses were randomly assigned to receive fluocinonide cream 0.1% on one arm and clobetasol propionate cream 0.05% on the other arm. Study medications were applied to disease-free target areas on the inner arms twice daily for 2 weeks. The epidermal thickness of pretreatment and posttreatment punch biopsy specimens was measured. Skin examinations were performed evaluating clinical signs of atrophy. No significant reduction in epidermal thickness was observed in the fluocinonide-treated sites (mean, -0.0318 mm; standard deviation, 0.0239; P=.1991). A significant reduction in epidermal thickness was seen in the clobetasol-treated sites (mean, -0.1825 mm; standard deviation, 0.0239; P<.0001). This reduction was significantly greater than results from sites treated with fluocinonide cream 0.1% (difference, -0.1507; standard deviation, 0.0131; P<.0001). Although topical corticosteroids often are the first-line treatment for patients with various dermatoses, a side effect of continuous use is cutaneous atrophy. Our study demonstrated that clobetasol propionate cream 0.05% caused a significantly greater reduction in epidermal thickness compared with fluocinonide cream 0.1% when used twice daily for 2 weeks (P<.001). However, neither drug caused significant clinical signs of atrophy.
Collapse
Affiliation(s)
- Annemarie Uliasz
- Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029, USA.
| | | | | | | | | |
Collapse
|
30
|
Soung J, Cohen J, Phelps R, Cohen SR. Case reports: minocycline-induced hyperpigmentation resolves during oral isotretinoin therapy. J Drugs Dermatol 2007; 6:1232-1236. [PMID: 18189065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Although disfiguring hyperpigmentation is a well-defined complication of minocycline therapy, modalities to reverse the phenomenon are unpredictable. We report a case of minocycline-induced, blue-black pigmentation in a 23-year-old Hispanic man, which resolved after treatment with oral isotretinoin for acne vulgaris.
Collapse
Affiliation(s)
- Jennifer Soung
- Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
| | | | | | | |
Collapse
|
31
|
Soung J, Muigai W, Amin N, Stern DK, Lebwohl MG. A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA). J Drugs Dermatol 2005; 4:290-4. [PMID: 15898283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
PUVA has become a common form of treatment for early stage mycosis fungoides (MF). The purpose of this retrospective study was to review the clinical data of 51 MF patients (96% stage IA or IB) treated with PUVA at the Mt. Sinai MF clinic over the past 20 years. We analyzed the efficacy, safety, and remission duration in patients who were treated with a modified PUVA regimen. Forty-four of 51 patients (86%) achieved complete clinical clearing for all stages after initial PUVA therapy. The mean duration of remission with maintenance treatment was more than 27 months (range: 3 weeks to 130 months). The mean duration of disease from start of first PUVA therapy for all patients was 4.8 years (range: 0.7 to 130 months). PUVA for patients with early-stage MF is a safe and effective therapeutic modality with prolonged disease-free remissions, however, PUVA alone was not adequate for more advanced disease.
Collapse
|
32
|
Cahill JD, Dapaah-Afriyie K, Badoe K, Soung J, Mileno MD. Malaria in Rhode Island: observations from 1990 to 1998. J Travel Med 2001; 8:100-2. [PMID: 11285169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Affiliation(s)
- J D Cahill
- Division of Infectious Diseases, Brown University School of Medicine, Providence, Rhode Island 02906, USA
| | | | | | | | | |
Collapse
|